Digestive System Neuroendocrine Tumor — Variants & evidence

Digestive System Neuroendocrine Tumor — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items (1 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E1
Dabrafenib + Trametinib + VemurafenibCombination	Digestive System Neuroendocrine TumorALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1430 BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited dura… (full text at CIViC) PMID 27048246 · Klempner et al., 2016 · Open in CIViC	civic
High1
Temozolomide	Pancreatic Neuroendocrine Tumor	Predictive	B	Supports Sensitivity Response	3	submitted	EID13033 Temozolomide (TMZ), the principal alkylating agent used in PanNET, drives acquisition of a hypermutator phenotype through direct mutagenesis. In a paired pre/post-TMZ cohort (23 patients), a hypermuta… (full text at CIViC) PMID 41244370 · Taboada et al., 2025 · Open in CIViC	civic

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.